Education
About Us
Working with TipRanks
Follow Us
Chimeric Therapeutics Ltd. (AU:CHM)
ASX:CHM
CHM Stock Chart & Stats
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.03
Previous CloseN/A
Volume2.58M
Average Volume (3M)2.05M
Market Cap
AU$11.34M
Enterprise ValueAU$14.47M
Total Cash (Recent Filing)AU$3.53M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.71
Next Earnings
Aug 28, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding2,268,209,700
10 Day Avg. Volume3,014,500
30 Day Avg. Volume2,054,362
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)21654.24
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Chimeric Therapeutics Ltd. News
PremiumCompany Announcements
Chimeric Therapeutics Lists Options on ASX to Boost Market Engagement
PremiumCompany Announcements
Chimeric Therapeutics Extends Entitlement Offer Deadline
PremiumCompany Announcements
Chimeric Therapeutics Announces Shareholder Structure Analysis
PremiumCompany Announcements
Chimeric Therapeutics Announces New ASX Quotation for OptionsPremiumCompany Announcements
Chimeric Therapeutics Launches $3.2 Million Entitlement Offer---
Options Prices
Currently, No data available
---
Ownership Overview
8.60% Insiders
―
Mutual Funds
― Other Institutional Investors
91.40% Public Companies and
Individual Investors
CHM FAQ
What was Chimeric Therapeutics Ltd.’s price range in the past 12 months?
Chimeric Therapeutics Ltd. lowest share price was <AU$0.01 and its highest was AU$0.03 in the past 12 months.
What is Chimeric Therapeutics Ltd.’s market cap?
Chimeric Therapeutics Ltd.’s market cap is AU$11.34M.
When is Chimeric Therapeutics Ltd.’s upcoming earnings report date?
Chimeric Therapeutics Ltd.’s upcoming earnings report date is Aug 28, 2025 which is in 123 days.
How were Chimeric Therapeutics Ltd.’s earnings last quarter?
Chimeric Therapeutics Ltd. released its earnings results on Feb 28, 2025. The company reported -AU$0.003 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.003.
Is Chimeric Therapeutics Ltd. overvalued?
According to Wall Street analysts Chimeric Therapeutics Ltd.’s price is currently Overvalued.
Does Chimeric Therapeutics Ltd. pay dividends?
Chimeric Therapeutics Ltd. does not currently pay dividends.
What is Chimeric Therapeutics Ltd.’s EPS estimate?
Chimeric Therapeutics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Chimeric Therapeutics Ltd. have?
Chimeric Therapeutics Ltd. has 2,268,209,700 shares outstanding.
What happened to Chimeric Therapeutics Ltd.’s price movement after its last earnings report?
Chimeric Therapeutics Ltd. reported an EPS of -AU$0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Chimeric Therapeutics Ltd.?
Currently, no hedge funds are holding shares in AU:CHM
---
Chimeric Therapeutics Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:CHM Sentiment 79%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth AU$800.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Fundamentals
Return on Equity
-180.09%
Trailing 12-Months
Asset Growth
-30.02%
Trailing 12-Months
Company Description
Chimeric Therapeutics Ltd.
Chimeric Therapeutics Ltd. (CHM) is a biotechnology company focused on the development of novel cell therapies for cancer treatment. The company leverages its expertise in chimeric antigen receptor T-cell (CAR-T) technology to design and develop next-generation therapies aimed at improving patient outcomes. Chimeric Therapeutics is committed to pioneering advanced approaches in immunotherapy, with a pipeline of products targeting various cancer indications.
---
---